Surgical Innovation Using Microbiome-Compatible Surgical Wound Management Platforms

Abstract

Wound healing is a complex, multifactorial process influenced by host factors and the local microbiome. Recent advances in surgical innovation have focused on developing microbiome-compatible wound management platforms to optimize healing outcomes, reduce infection rates, and improve patient recovery. This review explores the scientific rationale, clinical implications, and emerging evidence supporting the integration of microbiome-aware wound care interventions in surgical practice.

Introduction

Effective surgical wound management remains a cornerstone of perioperative care, impacting infection rates, healing trajectories, and healthcare costs. Traditional approaches have emphasized sterility and broad-spectrum antimicrobial strategies. However, mounting evidence underscores the importance of preserving a balanced wound microbiome to facilitate optimal tissue repair. Innovations in microbiome-compatible wound management platforms aim to harness the beneficial aspects of commensal microbial communities while mitigating pathogenic overgrowth. This review synthesizes contemporary research, epidemiological data, mechanistic insights, and guideline-based recommendations for clinicians seeking to implement microbiome-friendly strategies in the operating room and postoperative settings.

Epidemiology / Disease Burden

Surgical site infections (SSIs) represent a significant burden globally, accounting for 20-30% of healthcare-associated infections and affecting up to 5% of patients undergoing surgery. The consequences of SSIs include prolonged hospitalization, increased morbidity, and substantial economic costs. Chronic non-healing surgical wounds, often complicated by dysbiosis, further exacerbate this burden, particularly among high-risk populations such as the elderly, diabetics, and immunocompromised individuals. As antibiotic resistance escalates, the need for innovative, microbiome-compatible wound management strategies grows increasingly urgent within the surgical community.

Pathophysiology

Wound healing unfolds in distinct yet overlapping phases: hemostasis, inflammation, proliferation, and remodeling. The dynamic interplay between host immune responses and the local microbiome exerts a critical influence on each phase. Disruption of the commensal microbial balance—often through excessive use of antiseptics or systemic antibiotics—can impair epithelialization, increase pro-inflammatory cytokine production, and promote colonization by multidrug-resistant organisms. Conversely, a stable, diverse wound microbiome fosters regulatory immune signaling, enhances barrier function, and curbs pathogenic invasion. Microbiome-compatible wound platforms are engineered to support these beneficial interactions, leveraging biomaterials and bioactive compounds that preserve or restore microbial equilibrium without compromising infection control.

Risk Factors

Key risk factors for impaired wound healing and infection include patient comorbidities (e.g., diabetes mellitus, obesity, peripheral vascular disease), advanced age, malnutrition, immunosuppression, and prolonged operative times. Environmental factors such as hospital flora, perioperative antibiotic exposure, and the choice of wound dressings further modulate the wound microbiome. High-risk wounds—such as those resulting from trauma, contaminated surgeries, or procedures in anatomically challenging locations—are particularly susceptible to dysbiosis-driven complications. Recognizing these risk factors enables clinicians to tailor wound management strategies and select microbiome-compatible interventions for optimal patient outcomes.

Clinical Features

Clinically, wound healing disturbances manifest as delayed epithelialization, persistent exudate, erythema, edema, and signs of local or systemic infection. The presence of biofilms—multispecies microbial communities encased in an extracellular matrix—serves as a hallmark of chronic, recalcitrant wounds. These biofilms shield pathogens from host defenses and antibiotics, perpetuating inflammation and tissue breakdown. Microbiome-compatible wound management platforms target biofilm disruption while supporting beneficial microbial colonization, thereby promoting resolution of these challenging clinical presentations.

Diagnosis

Accurate assessment of surgical wounds entails both clinical evaluation and laboratory investigations. Traditional microbiological cultures, while informative, often underestimate microbial diversity and fail to distinguish beneficial from pathogenic organisms. Advanced molecular diagnostics—such as 16S rRNA gene sequencing and metagenomic analyses—have revolutionized the characterization of wound microbiota, enabling precision-guided management. Integration of these techniques into routine practice supports the identification of dysbiosis, guides targeted interventions, and facilitates monitoring of therapeutic efficacy in the context of microbiome-compatible wound care.

Treatment & Management

Conventional wound management has relied on mechanical debridement, antiseptic dressings, and empirical antibiotics to control infection and promote healing. However, these approaches may inadvertently disrupt commensal microbiota and foster resistance. Microbiome-compatible platforms incorporate materials such as hydrocolloids, alginates, and bioengineered matrices that maintain physiological moisture, minimize cytotoxicity, and enable selective microbial modulation. Adjunctive therapies—probiotic dressings, prebiotic substrates, and topical phage preparations—are increasingly explored to restore eubiosis, suppress pathogenic species, and accelerate tissue repair. Personalized wound care algorithms, informed by microbiome profiling, are emerging as a paradigm shift in surgical practice.

Recent Advances / Emerging Therapies

Recent years have witnessed rapid expansion in the development of microbiome-compatible wound management technologies. Innovations include dressings impregnated with beneficial bacteria (e.g., Lactobacillus spp.), engineered bacteriophage cocktails targeting resistant pathogens, and smart biomaterials that release anti-inflammatory or pro-healing factors in response to microbial metabolic cues. Clinical trials have demonstrated reduced infection rates, improved granulation, and faster wound closure with these novel platforms compared to traditional therapies. Integration of digital health tools—such as wearable sensors and telemedicine-enabled microbiome monitoring—further enhances personalized wound management and postoperative surveillance.

Guideline Recommendations

International guidelines increasingly recognize the importance of microbiome preservation in surgical wound care. The World Health Organization and Centers for Disease Control and Prevention advocate for judicious antibiotic use, avoidance of unnecessary antiseptics, and adoption of advanced dressings tailored to wound type and microbial milieu. Expert consensus supports the incorporation of microbiome-aware strategies—such as the use of prebiotic or probiotic dressings and molecular diagnostics—into multimodal wound management protocols, particularly for high-risk or non-healing wounds. Ongoing research and guideline updates will continue to shape best practices as the evidence base expands.

Conclusion

Microbiome-compatible surgical wound management platforms represent a transformative advance in perioperative care. By supporting beneficial host-microbe interactions, these innovations offer a pathway to reduced infection rates, accelerated healing, and improved patient outcomes. Continued research, interdisciplinary collaboration, and integration of emerging technologies will be essential in realizing the full potential of microbiome-aware wound care strategies in surgical practice.